Premenstrual dysphoric disorder
Wiki Number: PW175
Diagnosis: Premenstrual Dypshoric Disorder
World Patients: 1.8-5.8% of menstruating women.
Brain Area: serotonin receptors in the hippocampus and prefrontal cortex are affected by estrogen and progesterone activities
Symptoms: pain and mood changes for up to two weeks before menstruation.
Causes: genetic and fluctuating hormones during the menstrual cycle;
Medications: antidepressants, SSRIs, ovulation suppression with birth-control pills and GnRH analogues. SSRIs are most common & help 50%.
What It’s Like To Have Premenstrual Dysphoric Disorder
Amazon or Library Book: The PMDD Phenomenon
Click the book to link or order from Amazon.
Support Group” viciouscyclepmdd.com-iampt.org
(International Association for Premenstrual Disorder)
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Associated factors with Premenstrual syndrome and Premenstrual dysphoric disorder among female medical students: A cross-sectional studyby Vy Dinh Trieu Ngo on January 26, 2023
CONCLUSION: The prominent risk factors for Premenstrual Syndrome and Premenstrual Dysphoric Disorder were negative Rhesus blood type, menarche age, caffeine consumption, and self-reported depression.
- Altered visual cortex excitability in premenstrual dysphoric disorder: Evidence from magnetoencephalographic gamma oscillations and perceptual suppressionby Viktoriya O Manyukhina on December 30, 2022
Premenstrual dysphoric disorder (PMDD) is a psychiatric condition characterized by extreme mood shifts during the luteal phase of the menstrual cycle (MC) due to abnormal sensitivity to neurosteroids and unbalanced neural excitation/inhibition (E/I) ratio. We hypothesized that in women with PMDD in the luteal phase, these factors would alter the frequency of magnetoencephalographic visual gamma oscillations, affect modulation of their power by excitatory drive, and decrease perceptual spatial...
- Effects of acute estradiol and progesterone on perimenstrual exacerbation of suicidal ideation and related symptoms: a crossover randomized controlled trialby Tory A Eisenlohr-Moul on December 30, 2022
Female suicide attempts peak peri-menstrually-around the onset of menses-when the ovarian steroids estradiol (E2) and progesterone (P4) fall rapidly. Given preclinical evidence that withdrawal from either E2 or P4 can provoke behaviors consistent with elevated suicide risk, we hypothesized that withdrawal from one or both of these steroids contributes to perimenstrual exacerbation of suicidal ideation (SI) and related symptoms. In a randomized, controlled, double-blind crossover experiment...
- Management of Premenstrual Dysphoric Disorder: A Scoping Reviewby Sara V Carlini on December 28, 2022
Premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS) refer to physical, cognitive, or affective symptoms that arise in the late luteal phase and remit with menses. The present work is a clinically focused scoping review of the last twenty years of research on treatment for these disorders. A search of key terms using the PubMed/Medline, the Cochrane Library, Embase, and Web of Science databases was performed, and 194 studies of adult women met initial inclusion criteria for...